within Pharmacolibrary.Drugs.N_NervousSystem.N05B_Anxiolytics.N05BE01_Buspirone;

model Buspirone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.038,
    Cl = 3.611111111111111e-05,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.0053,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.025,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Buspirone</td></tr><tr><td>ATC code:</td><td>N05BE01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>130</td><td>L/hr</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Buspirone is an anxiolytic medication, primarily approved and used for the management of generalized anxiety disorder (GAD). It acts as a serotonin 5-HT1A receptor partial agonist and has minimal sedative or dependency potential compared to benzodiazepines. Buspirone is approved by regulatory agencies and commonly prescribed for anxiety disorders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers (both sexes), after a single oral dose administration.</p><h4>References</h4><ol><li><p>Gammans, RE, et al., &amp; LaBudde, JA (1989). Pharmacokinetics of buspirone in elderly subjects. <i>Journal of clinical pharmacology</i> 29(1) 72–78. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1989.tb03240.x\">10.1002/j.1552-4604.1989.tb03240.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2708551/\">https://pubmed.ncbi.nlm.nih.gov/2708551</a></p></li><li><p>Small, BG, et al., &amp; Johnson, TN (2023). Incorporation and Performance Verification of Hepatic Portal Blood Flow Shunting in Minimal and Full PBPK Models of Liver Cirrhosis. <i>Clinical pharmacology and therapeutics</i> 114(6) 1264–1273. DOI:<a href=\"https://doi.org/10.1002/cpt.3032\">10.1002/cpt.3032</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37620290/\">https://pubmed.ncbi.nlm.nih.gov/37620290</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05BE01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Buspirone;
